Psilocybin-Assisted Integration Therapy

Service List

Individual Therapy Group Counseling Psychedelic Therapy ExoMind TMS Treatment Mindfulness& Meditation Crisis Support Services

Initial Inquiry Form

125KB
Psychedelic Case Studies

3.6MB

Need Any Help ?

(310) 271-5875

Or Make An Appointment

Education, preparation, and integration—no drug provision

NuvoMind provides psychotherapy that helps you prepare for a legal psilocybin experience and integrate insights afterward, so meaningful moments translate into everyday change. Psilocybin is not FDA‑approved; NuvoMind does not prescribe, dispense, or administer psilocybin in California clinics, and we do not assist in sourcing controlled substances.

Image / Video Placeholder

How integration helps

We work on intentions and safety before, and meaning‑making and behavior change after, a legally obtained experience. Tools draw from cognitive and acceptance‑based therapies, mindfulness, and motivational interviewing—tailored to your goals.

Study highlights (education‑only)

Davis 2021 (JAMA Psych, MDD): ~71% response and ~54% remission at 4 weeks with psilocybin‑assisted therapy.
Goodwin 2022 (NEJM, TRD): single supported 25 mg dose improved MADRS at 3 weeks vs 1 mg; safety events reported.
COMPASS release 2022: ~30% remission at week 3 with 25 mg vs ~8% in low‑dose control (company summary of NEJM data).
Carhart‑Harris 2021 (NEJM): primary endpoint not significantly different vs escitalopram; several secondary measures (incl. remission) favored psilocybin.
Griffiths 2016 (cancer): substantial and sustained reductions in anxiety/depression vs control.
Ross 2016 (cancer): immediate, sustained improvements in anxiety/depression and quality of life.
Gukasyan 2022 (12‑mo follow‑up MDD): response ~75% and remission ~58% at 12 months among participants from the parent study.
Raison 2023 (JAMA): 25 mg psilocybin with support improved depression scores in MDD.
Frontiers 2024 review: among 5 MDD RCTs, ~60% reported beneficial primary outcomes; most showed anxiolytic benefits.
BMJ 2024 meta‑analysis: significant benefit of psilocybin vs placebo on depressive symptoms.

What we provide / do not provide

Provide: education, preparation, risk awareness, post‑experience integration, and coordination with your existing care (with consent).
Do not provide: prescribing/dispensing/administering psilocybin or assistance with sourcing; no claims of cure or guaranteed outcomes.

Book a Consultation Call Now

This page is informational and not a substitute for medical advice. Outcomes vary.